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ABSTRACT
The human trophoblast cell surface antigen 2 (TROP2) is overexpressed in 
many cancers. However, its effect on proliferation, migration and metastasis of 
gallbladder cancer remains unclear. In this study, we found that TROP2 was highly 
expressed in gallbladder cancer. Overexpression of TROP2 was associated with poor 
prognosis. Knockdown of TROP2 in gallbladder cancer cell lines strongly inhibited 
the cell proliferation, clone formation, invasion and migration in vitro, while TROP2 
overexpression had opposite effects. In addition, knockdown of TROP2 increased 
the expression of total PTEN, p-PTEN and PDK-1 but reduced p-AKT via PI3K/AKT 
pathway. TROP2 downregulation also inhibited vimentin and increased E-cadherin 
expression during epithelial-mesenchymal transition (EMT). Moreover, gallbladder 
cancer cells with TROP2 knockdown formed smaller xenografted tumors in vivo. In 
consistent with in vitro results, TROP2 inhibition decreased Akt phosphorylation, 
increased PTEN expression and postponed EMT of gallbladder cancer cells in vivo. 
In conclusion, we revealed that TROP2 promoted the proliferation, migration and 
metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing 
EMT. TROP2 could serve as a potential prognostic biomarker and therapeutic target 
for the clinical management of gallbladder cancer.
INTRODUCTION
Gallbladder cancer (GBC) is the most common 
malignancy of biliary system with low curative resection 
rate (10–30%), low response rate to chemotherapy, and 
poor prognosis (5-year survival less than 5%) [1, 2, 
3]. Thus, there is urgent need to reveal detailed signal 
pathways involved in GBC proliferation, migration and 
metastasis, which may provide potential prognostic 
biomarkers and therapeutic targets for the clinical 
management of GBC.
The human trophoblast cell surface antigen 2 
(TROP2), a 36-kDa cell-surface glycoprotein, also known 
as EGP-1, M1S1, GA733-1, belongs to the TACSTD gene 
family [4-6]. TROP2 was first discovered in trophoblast 
cell which was invasive and metastasizing cell of the 
placenta from the outer layer of the blastocyst [7]. TROP2 
was highly expressed in gastric cancer [8], cervical cancer 
[9], pancreatic cancer [10], colorectal cancer [11], lung 
cancer [12] and several types of stem cells [13]. TROP2 
overexpression has been reported to be associated with 
poor survival, tumor aggressiveness and metastasis [6]. 
It was also involved in many signaling pathways of cell 
proliferation, survival and self-renewal [14]. Cubas et al. 
reported that TROP2 contributed to tumor pathogenesis 
via ERK/MAPK pathway [15]. Liu et al. found that 
TROP2 promoted the proliferation and invasion of cervical 
cancer cells by regulating ERK signaling pathway [9]. 
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Although Chen et al. revealed that TROP2 overexpression 
was associated with poor prognosis of GBC [16], TROP2 
signal pathways and possible mechanisms are still unclear 
in GBC proliferation, migration and metastasis. We have 
previously characterized the cancer stem-like cells from 
GBC cells [17], and investigated their multidrug resistance 
[18, 19]. In this study, we revealed that TROP2 promoted 
the proliferation, migration and metastasis of GBC cells 
by regulating PI3K/AKT pathway and inducing epithelial-
mesenchymal transition (EMT). We suggest that TROP2 
could serve as a potential prognostic biomarker and 
therapeutic target for the clinical management of GBC.
RESULTS
Overexpression of TROP2 was associated with 
poor prognosis of GBC
As shown in Figure 1A and 1B, TROP2 was highly 
expressed in GBC, lower expressed in paracarcinoma, 
and undetectable in chronic cholecystitis tissues of both 
protein and mRNA levels. TROP2 protein expression 
was higher in advanced GBCs revealed by histology 
examination (Figure 1C). Overexpression of TROP2 
was closely correlated to gallstone presence, histological 
grade, tumor invasion, lymph node metastasis, TNM stage 
and poor survival (Table 1). Log-rank analysis showed that 
GBC survival was correlated to tumor size, histological 
grade, tumor invasion, lymph node metastasis and TROP2 
expression (Table 2 and Figure 1D). Cox regression 
analysis confirmed that TROP2 expression and tumor 
invasion were two independent prognostic factors for 
GBC (Table 2). These results suggest that overexpression 
of TROP2 was associated with poor prognosis of GBC.
Expression of TROP2 in human GBC cell lines 
after RNA interference or plasmid transfection
To further explore the function of TROP2 in GBC, 
its expression was examined in human GBC cell lines 
included NOZ, GBC-SD, OCUG-1, SGC-996 and EH-
GB-1 using western blot and quantitative real-time PCR. 
As shown in Figure 2A and 2B, TROP2 were detected in 
all of GBC cell lines at both protein and mRNA levels. 
Since GBC-SD and SGC-996 cells had higher TROP2 
expression among GBC cell lines, we selected these two 
Figure 1: TROP2 expression in GBC samples. (A) TROP2 protein was highly expressed in GBC, lower in paracarcinoma, and 
undetectable in chronic cholecystitis tissues (T: GBC, N: paracarcinoma, and C: chronic cholecystitis tissues). (B) TROP2 mRNA expression 
in GBC was significantly higher compared to paracarcinoma (167.06±50.71 VS 1.20±0.79, P<0.05). Columns, n=28; bars, S.D. P< 0.05, 
GBC compared with paracarcinoma. (C) TROP2 protein expression was higher in advanced GBCs revealed by IHC staining. No TROP2 
expression was detected in paracarcinoma. (D) Kaplan-Meier survival curve showed that GBC patients with high TROP2 expression had 
a worse prognosis.
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Table 1: Effects of TROP2 expression on clinicopathologic features of GBC
Parameter Case TROP2 expression χ2 P value
Low High
Sex
 Male 30 11 19 0.036 0.849
 Female 75 29 46
Age (years)
 ≤60 37 11 26 1.695 0.193
 >60 68 29 39
With gallstone
 Present 79 36 43 7.558 0.006
 Absent 26 4 22
Tumor size
 ≤3cm 38 11 27 2.113 0.146
 >3cm 67 29 38
Histological grade
 Well or morderate 54 33 21 24.973 0.000
 Poor 51 7 44
Tumor invasion (AJCC)
 Tis-T2 54 30 24 14.372 0.000
 T3-T4 51 10 41
Lymph node
 N0 58 33 25 19.422 0.000
 N1-2 47 7 40
TNM stage (AJCC)
 I-II 38 29 9 36.889 0.000
 III-IV 67 11 56
Table 2: Univariate and multivariate analysis of the prognostic factors for overall survival of GBC
Prognostic factors Univariate analysis Multivariate analysis
RR 95%CI P value RR 95%CI P value
Sex 1.062 0.678-1.644 0.793
Age (years) 1.118 0.772-1.809 0.443
Associated gallstone 0.848 0.525-1.372 0.503
Tumor size 0.006 0.001-0.045 0.000 0.000 0.169-4.183 0.846
Histological grade 0.084 0.045-0.157 0.000 0.387 0.124-1.206 0.102
Tumor invasion (AJCC) 0.103 0.056-0.189 0.000 0.352 0.183-0.678 0.002
Lymph node 0.113 0.063-0.200 0.000 0.795 0.271-2.281 0.670
TROP2 expression 0.259 0.163-0.412 0.000 0.463 0.274-0.782 0.004
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cell lines for further experiments. We then used lentiviral-
mediated shRNA plasmid transfection targeting TROP2 
for stable transfection. The RT-PCR results showed that 
endogenous TROP2 mRNA expression was significantly 
inhibited at 48 h after transfection in both GBC-SD and 
SGC-996 cells (Figure 2C). The pcDNA 3.1-TROP(+) 
lentiviral vector was transfected into GBC-SD and SGC-
996 cells for the gain-of-function study. RT-PCR results 
revealed that TROP2 expression was increased in stable 
transfection group compared to empty vector group 
(Figure 2C). Thus, we successfully established the GBC 
cells with TROP2 knockdown and overexpression for 
further experiments.
Effects of TROP2 on proliferation and clone 
formation of GBC cells
To investigate the effects of TROP2 on 
proliferation and clone formation, we performed MTT 
and clone formation assays in GBC cells (Figure 3A and 
3D). The GBC cells were cultured for 7 days and cell 
viabilities were tested each day. To exclude the possibility 
of off-target effect, the other two shRNAs (shTROP2-2 
and shTROP2-3) were used for TROP2 knockdown 
(Supplementary Figure 1A, 1B and Supplementary Table 
1). The scramble sh-RNA and an empty vector (Mock) 
were used as negative controls (Supplementary Figure 2). 
We found that the cell vitality significantly decreased in 
the shRNA-TROP2 group of GBC-SD cells from Day 5 
(P < 0.05, Figure 3B and Supplementary Figure 2) and in 
the shTROP2-2 and shTROP2-3 groups from Day 3 (P < 
0.05, Supplementary Figure 1C and 1D). We found that 
the number of colony formation in shRNA-TROP2 group 
of GBC-SD cells was lower than that of scramble group 
(P < 0.05, Figure 3E). Inversely, GBC-SD, NOZ and 
EH-GB-1 cells with TROP2 overexpression had stronger 
ability of proliferation and clone formation compared 
to the control groups (P < 0.05, Figure 3B, 3C, 3F and 
Supplementary Figure 3). TROP2 had the same effects 
on SGC-996 cell (Figure 3C, 3F, Supplementary Figure 
1B and 1D).
Effects of TROP2 on migration and invasion of 
GBC cells
We further examined the effects of TROP2 on 
migration and invasion of GBC-SD and SGC-996 cells. 
As shown in Figure 4A, cell migration in shRNA-
TROP2 groups was significantly lower than that of 
scramble groups (P < 0.05, Figure 4A), while TROP2 
overexpression had the opposite effects (P < 0.05, Figure 
4B). GBC cells with TROP2 downregulation had less 
invasive ability (P < 0.05, Figure 4C). As shown in 
Figure 4D and S3D, GBC cells showed higher invasive 
ability after increasing TROP2 expression. These results 
suggest that high expression of TROP2 can enhance the 
Figure 2: TROP2 expression in GBC cell lines. (A) The TROP2 protein expression of human GBC cell lines NOZ, GBC-SD, 
OCUG-1, SGC-996 and EH-GB-1B. (B) The TROP2 mRNA expression of human GBC cell lines NOZ, GBC-SD, OCUG-1, SGC-996 and 
EH-GB-1B. (C) TROP2 mRNA expressions of GBC-SD and SGC-996 cells after RNA interference and plasmid transfection. Cells were 
transfected with scramble sh-RNA and empty vector as negative controls. Each experiment was repeated three times.
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invasive and migration of GBC cells, which is a key fact 
in regulating the migration and invasion of GBC.
Effects of TROP2 on xenografted tumor growth
To investigate the function of TROP2 in vivo, 
GBC cells were injected subcutaneously into 6-week-old 
BALB/c-nu/nu mice. As shown in Figure 5A, the tumor 
weight of shRNA-TROP2 groups significantly reduced 
compared to the scramble groups of both GBC-SD and 
SGC-996 cells (P < 0.05), while TROP2 overexpression 
had the opposite effects (P < 0.05, Figure 5B). These 
results indicate that TROP2 depletion can effectively 
suppress GBC growth in vivo.
Figure 3: Effects of TROP2 on proliferation and clone formation of GBC-SD and SGC-996 cells. (A) Microscope images 
of GBC-SD and SGC-996 cell growth after TROP2 knockdown and overexpression. (B and C) Growth curves of GBC-SD and SGC-996 
cells after RNA interference or plasmid transfection. Graphs, mean of three experiments; bars, S.D. *P < 0.05, shTROP2 group compared 
with the control group. #P < 0.05, TROP2 overexpression group compared with the control group. Each experiment was repeated three 
times. (D) Microscope images of GBC-SD and SGC-996 cell clone formation after TROP2 knockdown and overexpression. (E and F) 
The number of clone formation of GBC-SD and SGC-996 cells after RNA interference or plasmid transfection. Columns, mean of three 
experiments; bars, S.D. Each experiment was repeated three times.
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Figure 5: Effects of TROP2 on xenografted tumor growth. (A) Tumor weight of GBC-SD and SGC-996 cells after RNA 
interference in nude mice at 6 weeks after implantation. (B) Tumor weight of GBC-SD and SGC-996 cells after plasmid transfection in 
nude mice at 6 weeks after implantation. Columns, n=8; bars, S.D. P < 0.05, shTROP2 group compared with the control group and TROP2 
overexpression group compared with the control group.
Figure 4: Effects of TROP2 on migration and invasion of GBC-SD and SGC-996 cells. (A and B) Cell migration of GBC-
SD and SGC-996 cells after RNA interference or plasmid transfection. (C and D) Cell invasion of GBC-SD and SGC-996 cells after RNA 
interference or plasmid transfection. Columns, mean of three experiments; bars, S.D. P < 0.05, TROP2 overexpression group compared 
with the empty vector group. Each experiment was repeated three times.
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TROP2 regulates PI3K/AKT pathway and 
induces EMT in vitro and in vivo
Next, we explored the mechanisms of proliferation, 
migration and metastasis promoted by TROP2 in GBC. 
EMT is defined as the transformation of epithelial cells 
into spindle cells with the loss of membrane E-cadherin 
expression and the gain of mesenchymal markers such as 
vimentin, which promotes tumor initiation, progression 
and metastasis in human mammary epithelial cells. We 
found that downregulation of TROP2 decreased vimentin 
and increased E-cadherin expression both in vitro and 
in vivo, while TROP2 overexpression had the opposite 
effects (Figure 6A, 6B and 7).
It has been reported that Akt pathway was involved 
in cell proliferation and migration [20]. PTEN is a dual-
phosphatase that negatively regulates AKT activity [21]. 
Loss of PTEN and activation of the PI3K/AKT pathway 
result in tumor progression and metastasis [20, 22-23]. We 
found that downregulation of TROP2 markedly decreased 
the expression of active Akt (phosphorylated at Thr308) in 
vitro (Figure 6C), while the expression of total Akt protein 
did not change significantly. TROP2 knockdown increased 
the expression of total PTEN, p-PTEN and PDK-1 
(Figure 6C). Thus, downregulation of TROP2 can inhibit 
Akt phosphorylation and increase PTEN expression. In 
consistent with the in vitro results, TROP2 inhibition 
decreased Akt phosphorylation and increased PTEN 
expression in vivo (Figure 7A and 7B), while TROP2 
overexpression had the opposite effects (Figure 6B and 
6D). Altogether, our data suggest that TROP2 is involved 
in the PI3K/AKT pathway and induced EMT both in vitro 
and in vivo.
DISCUSSION
Over the past 20 years, molecule-targeted drug has 
become an effective method in cancer therapy, especially 
for lung cancer and breast cancer [24-25]. However, until 
now, no specific targeted therapy has been developed for 
GBC. TROP2, originally identified in human trophoblast 
and choriocarcinoma cells, which was highly expressed in 
many cancers include pancreatic carcinoma [10], gastric 
carcinoma [8], lung carcinoma [12] and colorectal cancer 
[11]. Stoyanova et al. demonstrated that TROP2 controlled 
stem/progenitor self-renewal and tissue regeneration [26]. 
In this study, we found TROP2 was highly expressed in 
GBC, lower in paracarcinoma, and undetectable in chronic 
cholecystitis tissues at both protein and mRNA levels. 
The reason might be that TROP2 is an oncogene of GBC, 
which is remarkably associated with cancer development 
and progression [16]. Furthermore, overexpression of 
TROP2 was correlated to gallstone presence, histological 
grade, tumor invasion, lymph node metastasis, TNM 
stage and poor survival. Among them, gallstone has been 
considered as the important reason for the occurrence 
of GBC [27]. TROP2 expression was further confirmed 
as an independent prognostic factor for GBC by Cox 
regression. All these data suggest that TROP2 could serve 
as a potential prognostic biomarker and therapeutic target 
for the clinical management of GBC.
We also found that TROP2 is a key fact in 
proliferation, clone formation migration and invasion of 
GBC. The PI3K/AKT pathway governs many cellular 
processes, including cell growth, proliferation, metabolism 
and cellular architecture advantages [22-23]. By acting 
as a unique lipid phosphatase, PTEN acts as the major 
cellular suppressor of PI3K signaling and AKT activation 
[22]. PTEN negatively regulates PI3K/AKT signaling and 
is often inactivated by mutations (including deletions) 
in a variety of cancer types [22]. Over-activation of Akt 
has been recognized to induce oncogenic [20, 22-23] and 
modulate cell growth and survival in GBC [28, 29]. Roa et 
al. reported that loss of PTEN expression was associated 
with advanced GBC and poor prognosis [30]. Lunardi et 
al. identified the role of aberrant PI3K pathway activation 
in gallbladder tumorigenesis [31]. Furthermore, Goldstein 
et al. found that TROP2 expression was significantly 
increased during tumorigenesis caused by aberrant PI3K 
signaling [32]. Similar to these findings, we revealed that 
TROP2 regulates PI3K/AKT pathway and induces EMT 
both in vitro and in vivo. In contrast, Lin et al. observed 
low TROP2 expression in lung adenocarcinoma tissues 
compared to their normal counterparts [12]. They found 
TROP2 could attenuate IGF-1R signalling-mediated 
AKT activation through a direct binding of IGF1. This 
might be due to either the loss of heterozygosity or 
hypermethylation of the CpG island DNA of TROP2 
upstream promoter region, which have not been fully 
found in the other cancers.
EMT is a morphological change of tissues/cells 
from an epithelial form to a fibroblast-like mesenchymal 
form [33-34], which has been regarded as one of the most 
important processes in cancer invasion and metastasis 
[33]. During this process, epithelial cells lose their 
properties such as E-cadherin and acquire mesenchymal 
phenotypes such as vimentin [35-36]. Chen et al. found 
that high TROP2 expression was significantly associated 
with loss of E-cadherin and acquisition of vimentin [16]. 
Our data showed that TROP2 downregulation could inhibit 
vimentin expression and upregulate E-cadherin expression 
both in vitro and in vivo, while TROP2 overexpression had 
the opposite effects. These results indicate that TROP2 
plays an important role in regulating the process of EMT 
in GBC invasion and metastasis. Further study is needed 
to clarify whether Akt activation or EMT is affected by 
PTEN or E-cadherin.
In conclusion, we found that overexpression of 
TROP2 was associated with poor prognosis of GBC. 
TROP2 promotes the proliferation, migration and 
metastasis of GBC cells by regulating PI3K/AKT 
pathway and inducing epithelial-mesenchymal transition. 
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Figure 6: Effects of TROP2 on EMT and PI3K/AKT pathway in GBC-SD and SGC-996 cells in vitro. (A) Knockdown of 
TROP2 expression inhibited vimentin and increased E-cadherin protein expression. (B) Overexpression of TROP2 increased vimentin and 
decreased E-cadherin protein expression. (C) Knockdown of TROP2 increased total PTEN, p-PTEN and PDK-1 protein expression, but 
inhibited p-AKT expression. (D) Overexpression of TROP2 decreased total PTEN, p-PTEN and PDK-1 protein expression, but increased 
p-AKT expression.
Figure 7: Effects of TROP2 on EMT and PI3K/AKT pathway in vivo. (A) Immunohistochemical results of xenografted tumors 
showed that inhibition of TROP2 expression increased PTEN expression, decreased Akt phosphorylation, and postponed EMT progress 
(decreased vimentin and upregulated E-cadherin expression). (B) TROP2 overexpression decreased PTEN expression, and increased Akt 
phosphorylation and EMT progress (increased vimentin and downregulated E-cadherin expression).
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We suggest that TROP2 could serve as a potential 
prognostic biomarker and therapeutic target for the clinical 
management of GBC.
MATERIALS AND METHODS
Patients and clinicopathological data
The specimens were obtained between 2003 and 
2010 from 105 patients with pathologically confirmed 
GBC, who underwent primary tumor resection at 
Changzheng Hospital affiliated with the Second Military 
Medical University (Shanghai, China). Among the 105 
GBC cases, there were 30 males and 75 females with ages 
ranging from 31 to 92 years (mean age: 64.82 years). All 
specimens and fresh tissue samples had been confirmed by 
pathological diagnosis and were staged according to the 
7th AJCC-TNM classification of malignant tumors. The 
median follow-up period was 22.23 months (range, 1–70.5 
months). In this study, no patients received chemotherapy 
or radiotherapy before surgery. The clinicopathological 
information and patients’ medical history were 
documented during post-operative follow up. Prior to our 
scientific research, patient’s consent was obtained and this 
study was approved by the ethics committee of the Second 
Military Medical University.
Western blot analysis
Cellular proteins were extracted using radio-
immunoprecipitation assay (RIPA) buffer according to the 
method described by Cubas et al. [15]. Equal amount of 
proteins was electrophoresed on 12% SDS-polyacrylamide 
gel and transferred to a nitrocellulose membrane. The 
membrane was incubated for 1 h in blocking buffer (5% 
low-fat milk powder in TBS containing 0.1% Tween) 
and then incubated with the mouse antibody against 
human TROP2 (R&D Systems, Inc., Minneapolis, USA), 
vimentin, E-cadherin, PTEN, p-PTEN, PDK-1, AKT, and 
p-AKT (Abcam, Cambridge, UK) at 4°C for overnight 
and horseradish peroxidase-conjugated goat anti-mouse 
immunoglobulin (Sigma, St. Louis, MO, USA) for 1 h 
before detected by an enhanced chemiluminescence (ECL) 
system. GADPH was used as the loading control and 
anti-GADPH antibody was obtained from Cell Signaling 
Technology (Danvers, USA).
Quantitative real-time PCR and RT-PCR
Total mRNA was extracted using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the 
instruction of the manufacturer as previously used 
by Li et al. [37]. The cDNA was reverse-transcribed 
from 2 ug total RNA. Detection of PCR products was 
performed on a Light Cycler system (Roche Applied 
Science, Basel, Switzerland) using the SYBR Green I 
kit (TaKaRa Biotechnology, Dalian, China), according to 
the manufacturer’s instructions. Each sample was done 
in triplicate. The internal control for real-time PCR was 
β-actin. The relative expression level of the target gene 
was calculated and normalized to the relative expression 
detected in the corresponding control cells, which was 
defined as 1.0.
Total mRNA was extracted using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the 
instruction of the manufacturer. The cDNA of TROP2 
expression was reverse transcribed from 2 ug total RNA. 
β-actin was used as an internal control. The PCR was 
performed as follows: denaturation for 5min at 95°C, 30 
cycles of 95°C for 30s, 55°C for 45s and 72°C for 30s, 
then extended for 10 min at 72°C.
Immunohistochemistry
Immunohistochemistry (IHC) staining was 
performed using the standard immunoperoxidase staining 
procedure, and TROP2 expression in the specimens was 
evaluated according to the methods described by Fong et 
al. [10]. TROP expression was evaluated for each tissue 
sample by calculating a total immunostaining score as the 
product of a proportion and intensity score. The proportion 
score described the estimated fraction of positive stained 
tumor cells (0, none; 1, <10%; 2, 10-50%; 3, 51-80%; 
4, >80%). The intensity score represented the estimated 
staining intensity (0, no staining; 1, weak; 2, moderate; 
3, strong). The total score ranged from 0 to 12. The high 
expression of TROP2 was defined as a total score of 
more than 4 described by Fong et al. [10]. Expressions 
of vimentin, E-cadherin, p-AKT and PTEN in animal 
transplanted tumor paraffin tissue sections was adopted 
following the above experiment method.
Cell culture
The human GBC cell lines NOZ, GBC-SD, 
OCUG-1, SGC-996 and EH-GB-1 were purchased from 
the Shanghai Cell Institute National Cell Bank. NOZ 
and SGC-996 were cultured in RPMI-1640 medium 
(GibcoBRL, Gaitherburg, MD, USA). The remaining 
cell lines were cultured in Dulbecco’s Modified Eagles 
Medium (DMEM) (GibcoBRL, Gaitherburg, MD, USA). 
The media were supplemented with antibiotics and 10% 
newborn calf serum. Cells were cultured in a humidified 
atmosphere with 5% CO2 at 37 C.
RNA interference and plasmid transfection
As described by Zhang et al. [38], for lentivirus-
mediated silencing of TROP2, the short hairpin RNA 
(shRNA) effectively targeted human TROP2 to acquire the 
stabilized expression. The recombinant plasmid pGensil1.1-
TROP2-shRNA (including shTROP2, shTROP2-2 and 
shTROP2-3) was provided by Dr. Dai from Jiangsu 
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University. The GBC-SD and SGC-996 cells were infected 
with concentrated vector according to the manufacturer’s 
instructions. For the generation of stable GBC-SD and 
SGC-996 cells overexpressing human Trop2, a pcDNA 3.1-
TROP(+) vector (a kind gift from Dr. Yang from Shandong 
University) was utilized. For transfection, cells were seeded 
into 6-well plates and expected to be 50% confluency next 
day. Cells transfected with scrambled shRNA or empty 
vectors were considered as negative control. Lipofectamine 
2000 (Invitrogen) was used for transfection according to the 
manufacturer’s instructions. The relative levels of TROP2 in 
the transfected cells were examined by RT-PCR. Functional 
assays were performed 48 h after transfection.
Cell proliferation and clone formation assays
For cell proliferation study, growth curves of GBC-
SD and SGC-996 cells were determined by the MTT assay 
(Sigma-Aldrich Corp. St. Louis, MO USA), as described 
by Li et al. [17]. Approximately 2.0×103 cells per well were 
seeded in 96-well plates. After incubation time from day 1 
to day 7, 10 μL MTT (5 mg/ml) was added to each well and 
incubated at 37 C for 4 h. Afterwards, the culture medium 
was removed and 100 μL dimethyl sulphoxid (DMSO) 
(Invitrogen, Carlsbad, CA, USA) was added to each well. 
After shaking thoroughly for 10 min, the absorbance of 
each well was determined with a spectrophotometer at 
a wave length of 570 nm. Triplicate wells were used for 
each group. To examine clonogenic ability, GBC-SD and 
SGC-996 cells were plated at 500 cells per well in six-well 
culture dishes in culture media with 10% newborn calf 
serum. Triplicate wells were performed for each group. 
After 2 weeks, clones with ≥50 cells were scored under the 
microscope.
Cell migration and invasion assays
As described by Li et al. [17], a transwell assay was 
used to examine cell migration and invasion. 2×104 cells were 
plated in 300 μL of serum-free medium. The upper chamber is 
made with the Boyden chamber containing an 8 μm pore size 
membrane (BD Biosciences, San Jose, CA). In cell invasion 
studies the membranes were pre-coated with Matrigel (1 mg/
ml; BD Biosciences, San Jose, CA). In the lower chamber, 
500 μL of culture media containing 0.2% FBS were added. 
After 24 h, the chamber was removed, fixed, and stained with 
trypan blue. Cells in the upper chamber were removed using 
the alcohol. Cells migrating through the membrane and cells 
invading the matrix were photographed in three randomly-
selected fields and counted in average.
Tumorigenicity assay in vivo
Approval for the animal experiments was obtained 
from the ethics committee of the Second Military Medical 
University. To explore the tumorigenic capacity, 2×106 cells, 
sorted and suspended in 100 μL culture media containing 
0.2% FBS, were injected subcutaneously into 6-week old 
BALB/c-nu/nu mice. The mice were monitored every week 
for palpable tumor formation. After 6 weeks, the mice 
were sacrificed. Tumors were then dissected and weighed. 
Tumor tissues were fixed by methanol for subsequent 
immunohistochemical experiment.
Statistical analysis
Statistical analyses were performed using SPSS 
Statistics 18.0 software (SPSS Inc., Chicago, IL, USA) and 
results were considered statistically significant at p<0.05. 
Data were shown as mean values ± S.D., and some of 
the data were displayed in the form of chart. Differences 
between groups were evaluated by Student’s t test or one-
way ANOVA, and continuous variables were evaluated 
using Wilcoxon rank and inspection. Pearson chi-square 
test or Fisher’s exact test was used for analysis between the 
degree of staining and clinical parameters. Kaplan–Meier 
curves were plotted to describe the survival information 
by the log-rank test. Multivariate analysis was performed 
using a Cox’s proportional hazards regression model.
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